跳转到主要内容

Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks

Babies born after preterm prelabour rupture of membranes (PPROM) between 16 and 26 weeks of pregnancy are prone to underdevelopment of the lungs. When the membranes containing the fluid that surrounds the baby (amniotic fluid) rupture, a shortage of this fluid can occur, a condition that is called oligohydramnios. Oligohydramnios is thought to interfere with normal lung development so that it is delayed, resulting in a condition that is called pulmonary hypoplasia.

Pulmonary hypoplasia can present as severe breathing problems or as milder and even transient breathing problems. It can be accompanied by bleeding in the lung and can also result in chronic breathing problems due to scarring of lung tissue. There may also be neurological complications, fetal deformities and neonatal sepsis with oligohydramnios.

Replacement of fluid via a needle passed through the abdominal wall in the uterine cavity and into a pocket of amniotic fluid, (transabdominal amnioinfusion) under ultrasound guidance has been proposed to improve pregnancy outcome. Most clinical experience suggests that amnioinfusion is safe for both the mother and the baby, however, we did not identify any randomised trials of transabdominal amnioinfusion following PPROM before 26 weeks for inclusion in this review. Currently, there is no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios following  rupture of fetal membranes before 26 weeks for improving birth outcomes.

研究背景

Preterm prelabour rupture of membranes (PPROM) before 26 weeks can delay lung development and can cause pulmonary hypoplasia, as a result of oligohydramnios. Restoring the amniotic fluid volume by transabdominal amnioinfusion might prevent abnormal lung development and might have a protective effect for neurological complications, fetal deformities and neonatal sepsis.

研究目的

To assess the effectiveness of transabdominal amnioinfusion in improving perinatal outcome in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks.

检索策略

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013).

纳入排除标准

All randomised controlled trials comparing transabdominal amnioinfusion with no transabdominal amnioinfusion. Cluster- or quasi-randomised trials were not eligible for inclusion. In cases where only an abstract was available, we attempted to find the full articles.

资料收集与分析

Two review authors assessed trials for inclusion. No eligible trials were identified.

主要结果

There are no included studies.

作者结论

There is currently no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks for improving perinatal outcome. Further research examining the effects of this intervention is needed. Two randomised controlled trials are ongoing but final data have not yet been published.

引用文献
Van Teeffelen S, Pajkrt E, Willekes C, Van Kuijk SMJ, Mol BWJ. Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009952. DOI: 10.1002/14651858.CD009952.pub2.

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置